Copyright
©The Author(s) 2015.
World J Respirol. Nov 28, 2015; 5(3): 180-187
Published online Nov 28, 2015. doi: 10.5320/wjr.v5.i3.180
Published online Nov 28, 2015. doi: 10.5320/wjr.v5.i3.180
Group | Treatment | Ref. | Design | patients | Outcome | Results | P vaule | Evidence level |
Hormonal | Oral or intramuscular progesterone | Beynon et al[68] | Case-series | 3 | Premenstrual dips in peak flow | 3 eliminated premenstrual dips in peak flow | NS | 4 |
Estrogen | Ensom et al[25] | Cross-over trial | 12 (mild severity) | Asthma Quality of Life Questionnaire, FEV1 | No differences | NS | 1b | |
Ensom et al[69] | Case report | 1 (severe asthma) | Symptoms, pulmonary function, peak flow | Improved | N/A | 4 | ||
OC | Murphy et al[18] | Case-series | 28 (16 with PMA) | OC use (%) | 5.42% in Non PMA 6.38% in PMA | NS | 4 | |
Tan et al[44] | Cross-sectional study | 18 (9 taking OC) | Changes between follicular and luteal phases in airway reactivity and peak flow | Changes in patients not taking OC; No changes in patients taking OC | 0.03 NS | 4 | ||
Derimanov et al[70] | Case report | 1 | Deterioration of asthma, decline of pulmonary function tests | After discontinuing the contraceptives, her condition returned to baseline | N/A | 4 | ||
Gonadotropin analogues | Murray et al[71] | Case report | 1 | Respiratory symptoms, PEFR dips premenstrual and prednisolone dosage and hospital admissions | Improvement | N/A | 4 | |
Anti-inflamma-tory | Anti-leukotrienes: pranlukast | Nakasato et al[19] | Pre-post study | 5 | Respiratory symptoms, PEFR | Improved asthma symptom scores, inhibited maximal decreases in PEFR | < 0.05 < 0.01 | 4 |
Anti-leukotrienes: montelukast | Pasaoglu et al[41] | Pre-post study | 24 mild asthma-tics (11 with PMA) | PEFR and symptom scores | Improvement in PEFR variability and symptom scores in women with PMA. No differences in women without PMA | 0.005 0.002 | 4 | |
Prostaglandin synthesis inhibitors: sodium meclofenomate | Shimoda et al[72] | Cross-over trial | 17 PMA | Peak flow, symptoms score | Improvement in peak flow during the early premenstrual period. No effect on the exacerbation of asthma during the late premenstrual period and early menstruation | 0.025 NS | 2 | |
Others | Phytoestrogens soy genistein | Bime et al[77] | Case series | 300 poorly controlled asthma | FEV1 and asthma control | Participants with little or no genistein intake had a lower baseline FEV1 and poorer asthma control than those with a moderate or high intake | 0.01 0.001 | 4 |
Phytoestrogens soy isoflavone | Smith et al[78] | Clinical trial | 386 poorly controlled asthma | FEV1 at 24 wk symptoms, episodes of poor asthma control, asthma control test score | Not result in improved lung function or clinical outcomes | NS | 1b |
- Citation: Pereira-Vega A, Sánchez-Ramos JL. Questions relating to premenstrual asthma. World J Respirol 2015; 5(3): 180-187
- URL: https://www.wjgnet.com/2218-6255/full/v5/i3/180.htm
- DOI: https://dx.doi.org/10.5320/wjr.v5.i3.180